SCHEMBL2770536

SCHEMBL2770536

COC(=O)c1ccc(I)c2c1CCc1ccccc1C2=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.47
MITF O75030 1/20 0.47
ALDH1A1 P00352 4/20 0.42
KDM4E B2RXH2 2/20 0.42
HPGD P15428 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
CES1 P23141 1/20 0.41
AKR1B1 P15121 2/20 0.39
KMT2A Q03164 4/20 0.39
MEN1 O00255 3/20 0.39
TSHR P16473 2/20 0.39
HTT P42858 1/20 0.39
MAPK10 P53779 1/20 0.39
PTK2B Q14289 1/20 0.39
NCOA1 Q15788 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
NCOA3 Q9Y6Q9 1/20 0.39
HSD17B10 Q99714 1/20 0.38
TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2768323 0.84 PTPRC (0.43) MAPTMITFALDH1A1KDM4EHPGD
SCHEMBL7210611 0.79 MAPT (0.50) MAPTMITFALDH1A1KDM4EHPGD
SCHEMBL2770097 0.75 AKR1B1 (0.43) MAPTALDH1A1KDM4EHPGDL3MBTL1
SCHEMBL24353347 0.70 CES1 (0.61) L3MBTL1CES1TDP1PKM
SCHEMBL27849729 0.70 TRPA1 (0.51) MAPTALDH1A1KDM4EHPGDL3MBTL1
SCHEMBL11523218 0.68 MAPT (0.49) MAPTALDH1A1KDM4EHPGDL3MBTL1
SCHEMBL8142034 0.68 SRD5A1 (0.56) MITFALDH1A1KDM4EHPGDL3MBTL1
SCHEMBL9372469 0.68 MAPK14 (0.57) MAPTALDH1A1KDM4EHPGDL3MBTL1
SCHEMBL11518121 0.68 POLB (0.43) MAPTALDH1A1KDM4EHPGDL3MBTL1
SCHEMBL2768852 0.68 TSHR (0.53) MAPTALDH1A1KDM4EHPGDL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1479670-B1 NOVEL FUSED RING INDAZOLE COMPOUNDS EISAI R&D MAN CO LTD (JP) 2010-04-21 EP disclosed
EP-1479670-B1 NOVEL FUSED RING INDAZOLE COMPOUNDS EISAI R&D MAN CO LTD (JP) 2010-04-21 EP disclosed
US-7390797-B2 Fused indazole compounds EISAI CO., LTD. (JP) 2008-06-24 US disclosed
US-7390797-B2 Fused indazole compounds EISAI CO., LTD. (JP) 2008-06-24 US disclosed
US-7390797-B2 Fused indazole compounds EISAI CO., LTD. (JP) 2008-06-24 US disclosed
US-20060111419-A1 Novel fused indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2006-05-25 US disclosed
EP-1479670-A1 NOVEL FUSED RING INDAZOLE COMPOUNDS Eisai Co., Ltd. (JP) 2004-11-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111419-A1 Novel fused indazole compounds MAP2K3, MAP3K11, MAP2K2 MAPT 2110/4885MITF 2286/4885ALDH1A1 1751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.